Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zibotentan + carboplatin + paclitaxel
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination regimen of three drugs: **zibotentan**, a selective endothelin A receptor (ETAR) antagonist; **carboplatin**, a platinum-based chemotherapeutic that causes DNA crosslinking and apoptosis; and **paclitaxel (Taxol)**, a microtubule-stabilizing agent that inhibits cell division. Zibotentan blocks ETAR-mediated signaling, which is implicated in tumor proliferation, survival, angiogenesis, and invasion, thereby potentiating the effects of cytotoxic agents. This combination has been evaluated primarily in the context of ovarian cancer, aiming to enhance antitumor efficacy compared to chemotherapy alone. Preclinical models and randomized phase II clinical studies have tested this combination to determine its effect on tumor response and progression-free survival in platinum-sensitive relapsed ovarian cancer[1][3][5].
- Other names
- zibotentan + carboplatin + paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNAEDNRA (Endothelin receptor type A)
Beyond the preview
Go deeper on zibotentan + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zibotentan + carboplatin + paclitaxel.